Orlistat is an anti-obesity drug that works by inhibiting the triglycerides uptake from the intestines.
Orlistat 60 mg 3 times a day combined with hypocaloric diet in persons with BMI ≥ 28-43 produced an absolute weight loss of 2,2 kg after 6 months of treatment. After 1 year of treatment the participants sustained a weight loss of 3 – 3,6 kg.
In the studies leading to approval of orlistat 60 mg 50 % of the participants achieved a weight loss of ≥ 5 % of the baseline body weight. Evidence has demonstrated that this level of weight loss is beneficial to parameters of the common co-morbidities of obesity, such as hypertension, diabetes and hypercholesterolemia.
Generally there is a significantly higher weight loss with orlistat 120 mg x 3 than with 60 mg x 3.
Orlistat does not induce a clinical relevant weight loss in patients with BMI below 28 kg/m2.
10 – 20 % will experience fatty oily stool, faecal urgency and increased defecation.
The price for 6 months of treatment is 2.340 Dkr., corresponding to 13 Dkr. a day.
In comparison the double dose, which is on prescription and leads to a significant higher weight loss, costs 3.600 Dkr. for 6 months of treatment,or 20 Dkr. a day.
IRF states, that the effect of orlistat is minor, and is only recommended with precautions in very obese persons and should always be combined with non-pharmacological treatment as diet and exercise.
alli is not under the rules of general reimbursement
alli was marketed the 4th of May 2009.